119 related articles for article (PubMed ID: 23333300)
1. Stat3 inhibits WTX expression through up-regulation of microRNA-370 in Wilms tumor.
Cao X; Liu D; Yan X; Zhang Y; Yuan L; Zhang T; Fu M; Zhou Y; Wang J
FEBS Lett; 2013 Mar; 587(6):639-44. PubMed ID: 23333300
[TBL] [Abstract][Full Text] [Related]
2. Berberine inhibits Wilms' tumor cell progression through upregulation of Wilms' tumor gene on the X chromosome.
Liu Y; Liu S
Mol Med Rep; 2013 Nov; 8(5):1537-41. PubMed ID: 24002362
[TBL] [Abstract][Full Text] [Related]
3. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
Wegert J; Wittmann S; Leuschner I; Geissinger E; Graf N; Gessler M
Genes Chromosomes Cancer; 2009 Dec; 48(12):1102-11. PubMed ID: 19760609
[TBL] [Abstract][Full Text] [Related]
4. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
5. Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.
Wang H; Shen Y; Sun N; Jiang YP; Li ML; Sun L
Chin Med J (Engl); 2012 May; 125(10):1733-9. PubMed ID: 22800892
[TBL] [Abstract][Full Text] [Related]
6. Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity.
Buettner R; Huang M; Gritsko T; Karras J; Enkemann S; Mesa T; Nam S; Yu H; Jove R
Mol Cancer Res; 2007 Aug; 5(8):823-32. PubMed ID: 17699108
[TBL] [Abstract][Full Text] [Related]
7. SIPAR negatively regulates STAT3 signaling and inhibits progression of melanoma.
Ren F; Su F; Ning H; Wang Y; Geng Y; Feng Y; Wang Y; Zhang Y; Jin Z; Li Y; Jia B; Chang Z
Cell Signal; 2013 Nov; 25(11):2272-80. PubMed ID: 23917203
[TBL] [Abstract][Full Text] [Related]
8. Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor.
Rong Y; Cheng L; Ning H; Zou J; Zhang Y; Xu F; Liu L; Chang Z; Fu XY
Cancer Res; 2006 Aug; 66(16):8049-57. PubMed ID: 16912181
[TBL] [Abstract][Full Text] [Related]
9. Stat3 induces oncogenic Skp2 expression in human cervical carcinoma cells.
Huang H; Zhao W; Yang D
Biochem Biophys Res Commun; 2012 Feb; 418(1):186-90. PubMed ID: 22252296
[TBL] [Abstract][Full Text] [Related]
10. Wilms tumor gene on X chromosome (WTX) inhibits degradation of NRF2 protein through competitive binding to KEAP1 protein.
Camp ND; James RG; Dawson DW; Yan F; Davison JM; Houck SA; Tang X; Zheng N; Major MB; Moon RT
J Biol Chem; 2012 Feb; 287(9):6539-50. PubMed ID: 22215675
[TBL] [Abstract][Full Text] [Related]
11. WTX mutations can occur both early and late in the pathogenesis of Wilms tumour.
Fukuzawa R; Holman SK; Chow CW; Savarirayan R; Reeve AE; Robertson SP
J Med Genet; 2010 Nov; 47(11):791-4. PubMed ID: 20679664
[TBL] [Abstract][Full Text] [Related]
12. Clinical, Pathologic, and Genetic Features of Wilms Tumors With WTX Gene Mutation.
Alexandrescu S; Akhavanfard S; Harris MH; Vargas SO
Pediatr Dev Pathol; 2017; 20(2):105-111. PubMed ID: 28326956
[TBL] [Abstract][Full Text] [Related]
13. Pathology, genetics and cytogenetics of Wilms' tumour.
Md Zin R; Murch A; Charles A
Pathology; 2011 Jun; 43(4):302-12. PubMed ID: 21516053
[TBL] [Abstract][Full Text] [Related]
14. STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes.
Krejci P; Salazar L; Goodridge HS; Kashiwada TA; Schibler MJ; Jelinkova P; Thompson LM; Wilcox WR
J Cell Sci; 2008 Feb; 121(Pt 3):272-81. PubMed ID: 18198189
[TBL] [Abstract][Full Text] [Related]
15. [The tumor suppressor gene WTX, mutated in Wilms tumours, is a member of the beta-catenin destruction complex].
Angers S
Med Sci (Paris); 2007 Nov; 23(11):1025-7. PubMed ID: 18021721
[No Abstract] [Full Text] [Related]
16. An RNA-binding protein alphaCP-1 is involved in the STAT3-mediated suppression of NF-kappaB transcriptional activity.
Nishinakamura H; Minoda Y; Saeki K; Koga K; Takaesu G; Onodera M; Yoshimura A; Kobayashi T
Int Immunol; 2007 May; 19(5):609-19. PubMed ID: 17383969
[TBL] [Abstract][Full Text] [Related]
17. Wilms tumor genetics: a new, UnX-pected twist to the story.
Huff V
Cancer Cell; 2007 Feb; 11(2):105-7. PubMed ID: 17292822
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway.
Brock M; Trenkmann M; Gay RE; Michel BA; Gay S; Fischler M; Ulrich S; Speich R; Huber LC
Circ Res; 2009 May; 104(10):1184-91. PubMed ID: 19390056
[TBL] [Abstract][Full Text] [Related]
19. The expression of IL-6 and STAT3 might predict progression and unfavorable prognosis in Wilms' tumor.
Zhang LJ; Liu W; Gao YM; Qin YJ; Wu RD
Biochem Biophys Res Commun; 2013 Jun; 435(3):408-13. PubMed ID: 23665320
[TBL] [Abstract][Full Text] [Related]
20. Cancer. Converging on beta-catenin in Wilms tumor.
Nusse R
Science; 2007 May; 316(5827):988-9. PubMed ID: 17510350
[No Abstract] [Full Text] [Related]
[Next] [New Search]
